InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,501.56
(
0.34%
)
US TECH 100
19,319.00
(
0.28%
)
Dow Jones
39,271.02
(
0.27%
)
Brent Oil
84.97
(
-0.52%
)
Bitcoin
60,820.00
(
-1.28%
)
Post# of 5468
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Preciouslife1

Send PM Follow Ignore
Followers 89
Posts 19174
Boards Moderated 4
Alias Born 11/05/2005

Preciouslife1

Re: None

Sunday, 12/26/2021 12:02:39 AM

Sunday, December 26, 2021 12:02:39 AM

Post# of 5468
Article regarding mAbs currently authorized.

"Data suggests that two common monoclonal antibody treatments—Eli Lilly’s bamlanivimab plus etesevimab and Regeneron’s REGEN-COV (casirivimab and imdevimab)—are not effective against the Omicron variant of COVID-19. However, preclinical findings have shown that GlaxoSmithKline’s Vir (sotrovimab) works well against Omicron in a lab setting...

Omicron is now the dominant strain of SARS-CoV-2, the virus that causes COVID-19, in the U.S.: It’s responsible for 73.2% of COVID-19 cases in the country, according to data from the Centers for Disease Control and Prevention (CDC)."

https://www.yahoo.com/lifestyle/most-monoclonal-antibody-treatments-dont-143000016.html

Bull-markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria .. Sir John Templeton
Make your Life a Mission .... NOT an Intermission. † §|PL1|§

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up